WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more

Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome

By LabMedica International staff writers
Posted on 22 Feb 2024

Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Antiphospholipid syndrome (APS) is an autoimmune disorder that typically presents as venous or arterial thrombosis and/or pregnancy loss. Diagnosing APS can be difficult as its symptoms often resemble those of other diseases. Prompt diagnosis is essential to avoid complications, unnecessary medical procedures, and escalating healthcare costs. Now, a new pair of reagents can enable early diagnosis of APS, one of the hard-to-diagnose autoimmune diseases.

Werfen’s (Barcelona, Spain) Aptiva APS Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents are immunoassays that utilize Aptiva particle-based multi-analyte technology (PMAT) for the semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM autoantibodies in human serum and citrated plasma. They serve as a diagnostic aid for both primary and secondary APS, in conjunction with other laboratory findings.

The Aptiva system is a fully automated, multi-analyte system, representing the latest advancement in high throughput analyzers for autoimmunity and immunology laboratories. Utilizing PMAT, Aptiva can process up to 120 APS tests per hour, allowing laboratories to handle their workload more efficiently and with reduced manual intervention. Werfen has recently announced that it has received the CE (Conformité Européenne) mark for its Aptiva APS IgG and IgM reagents. These new reagents not only complement Werfen's existing Aptiva Celiac Disease and Connective Tissue Diseases (CTD) Essential reagents but also extend the range of CE Marked analytes detectable by Aptiva to a total of 19.

"Early diagnosis is crucial in preventing complications as well as unnecessary procedures and increased healthcare costs,” said Michael Mahler, PhD, Vice President of Research and Development at Werfen. “Aptiva APS IgG and APS IgM deliver expanded information to clinicians to help with the diagnosis and management of patients with autoimmune diseases."

Related Links:
Werfen